Crown Bioscience Announces Record Breaking Growth With First 2017 Quarter Results
(Thomson Reuters ONE) -
SANTA CLARA, Calif., May 19, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a
wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a
global drug discovery and development services company providing translational
platforms to advance oncology and metabolic disease research, announces
continued growth in 2017 with dramatic first quarter results.
In Q1 17 revenue reached NT$493 million, a 34% YOY (year-over-year) growth.
Gross margin reached 49.3% with EPS (earnings per share) of NT$0.13. With the
strong demand for Oncology and Immunology therapy, the company anticipates
sustained revenue growth and increased profitability through 2017.
To achieve this growth CrownBio leveraged its existing platforms of patient-
derived xenograft (PDX) and cell line derived xenograft pharmacology models, and
expanded immuno-oncology translatable models while broadening the portfolio
offering to inflammatory disease. This extensive portfolio supports the
therapeutic continuum of Oncology, Cardiovascular, Metabolic, and Inflammatory
disease research.
"The double and triple digit growth regionally, proves CrownBio's global reach
and strong local presence is servicing our client base with sound scientific
offerings," said Laurie Heilmann, SVP of Global Strategy, Business Development
and Marketing, "Our Immuno-Oncology, Cardiovascular, and Metabolic translatable
models, along with strong performance in Europe, US, and the Western APAC region
were significant contributors to the growth."
Continued diversity across their service offerings, while remaining client
centric, has enabled CrownBio to secure confidence by demonstrating growth in
75% of the top tier pharma companies. "CrownBio brings clarity to drug discovery
with end to end solutions that help recognize the next clinical candidate
sooner," said Dr. Jean-Pierre Wery, CEO. "We will further advance preclinical
and clinical research through accelerating development of technologies,
including biomarker discovery and precision diagnosis that are needed to bring
the right molecule to market."
For more information on CrownBio's commitment to furthering the field of
oncology and metabolic disease drug discovery, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company
providing translational platforms to advance oncology and metabolic disease
research. With an extensive portfolio of relevant models and predictive tools,
Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. marketing(at)crownbio.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via GlobeNewswire
Datum: 19.05.2017 - 14:03 Uhr
Sprache: Deutsch
News-ID 543738
Anzahl Zeichen: 3355
contact information:
Town:
Santa Clara
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 146 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crown Bioscience Announces Record Breaking Growth With First 2017 Quarter Results"
steht unter der journalistisch-redaktionellen Verantwortung von
Crown Bioscience Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
